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Objectives: Current guidelines tell us that intervention in severe necrotizing pancreatitis ought to be
performed as late as possible. However, when pancreatic necrosis becomes infected, the necrotic tissue
needs to be removed. Unfortunately, bacterial infection can only be proven by invasive methods.
Methods: Necrotizing pancreatitis with sterile or infected necrosis was induced in mice. Mice serum
samples were examined by antibody-based protein array. After identifying candidate proteins that
showed strong regulation, the serum concentration of these proteins was examined by sandwich ELISA.
Then, human serum samples were collected from patients with mild pancreatitis, severe pancreatitis
with and without pancreatic necrosis and patients with microbiologically proven infection of pancreatic
necrosis. These serum samples were then analyzed by sandwich ELISA.
Results: In mice 6 proteins were strongly up-regulated and were further investigated by ELISAs. Of these
proteins, CXCL16 and TRANCE (RANKL) concentrations were analyzed in human serum samples. CXCL16
and TRANCE were increased in patients with pancreatic necrosis and abdominal infection. Receiver
operated characteristics showed that CXCL16 was superior in predicting infected pancreatic necrosis
when compared to C-reactive protein and TRANCE.
Conclusions: Serum CXCL16 is increased in severe pancreatitis with infected pancreatic necrosis and
identiﬁes patients who beneﬁt from surgical necrosectomy.
Copyright © 2015, IAP and EPC. Published by Elsevier India, a division of Reed Elsevier India Pvt. Ltd. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
The natural course of severe acute necrotizing pancreatitis is
characterized by two phases with high lethality [1]. During the ﬁrst
two weeks, a massive systemic inﬂammatory response syndrome
(SIRS) leads to multi-organ dysfunction and triggers a subsequent
compensatory anti-inﬂammatory response syndrome. The
following immunosuppression facilitates a variety of bacterial and
fungal infections with ensuing sepsis [2]. While the majority of
patients with severe necrotizing pancreatitis slowly recover, 15%e
30% of these patients die from the disease [3]. Severe pancreatitis is
correlated with infection of pancreatic necrosis, and in the clinicaland Visceral Surgery, Uni-
burg, Germany. Tel.: þ49 761
(U.A. Wittel).
by Elsevier India, a division of Reedroutine C-reactive protein and procalcitonin are monitored to
identify these patients [4]. Unfortunately, monitoring C-reactive
protein and procalcitonin is unspeciﬁc and has no direct thera-
peutic implications so that to date, infection of pancreatic necrosis
can only be proven invasively by ﬁne needle aspiration and sub-
sequent microbiological analyses or suspected radiologically by
detection of gas bubbles in areas of pancreatic necrosis [5,6].
Especially in patients with high severity scores and known peri-
pancreatic ﬂuid collections or pancreatic necrosis, infected
pancreatic necrosis may require drainage and debridement of
infected necrotic tissue [7]. The indication for intervening must be
restrictive since only patients with infection of pancreatic necrosis
beneﬁt from intervention, while patients with sterile necrosis,
despite their often equally severe clinical course, show little to no
beneﬁt from intervention [8]. Therefore, the diagnosis of infection
in pancreatic necrosis is of exceptional clinical relevance in a col-












Age [years] 52.75 ± 2.45 46.71 ± 2.75 42.15 ± 5.16
Male 8 (67%) 18 (90%) 14 (100%)
Female 4 (33%) 2 (10%) 0 (0%)
Days after onset
of symptoms
3.83 ± 0.46 16.15 ± 1.73 16.57 ± 2.52
Operation 0 (0%) 1 (5%) 14 (100%)
Respiratory
failure
0 (0%) 21 (100%) 13 (93%)
Dialysis 0 (0%) 9 (43%) 8 (57%)
Vasopressor
support
0 (0%) 20 (95%) 12 (86%)
CT or MRI scan 7 (58%) 21 (100%) 14 (100%)
FNA 0 (0%) 13 (62%) 9 (64%)
Extraabdominal
infection
0 (0%) 3 (14%) 3 (21%)
Death 0 (0%) 2 (10%) 3 (21%)
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blood test, we screened for differentially regulated serum proteins
in a mouse model of necrotizing pancreatitis, comparing animals
with infected versus sterile pancreatic necrosis [9]. The expression
of key proteins was further examined in serum samples derived
from patients with secondary infected necrotizing pancreatitis and
compared to patients with equally severe clinical course but sterile
necrosis as well as control patients with mild acute pancreatitis.
Materials and methods
Animal procedures
Animal procedures were conducted according to the Federation
of European Laboratory Animal Science Associations guidelines and
approved by the local animal welfare committee. All procedures
were described in detail previously [9]. Shortly, 105 male Balb/c
mice (Charles River, Sulzfeld, Germany) were housed under stan-
dard conditions with a 12 h dark/light circle, standard pellet diet,
and water ad libitum. 5 animals per group were used for each
treatment and duration. Anesthesia was performed with 1-Chloro-
2,2,2-triﬂuoroethyldiﬂuoromethylether (Isoﬂuorane, Abbott, Baar,
Switzerland) and buprenorphine 0.15 mg/kg (Essex, Luzern,
Switzerland). Throughout the course of experiments, 0.15 mg/kg
buprenorphine diluted in 0.5 ml were administered at intervals of
8 h. Administering 2 ml/kg 4% sodium taurocholate solution fol-
lowed by 2 ml/kg saline into the distal common bile duct induced
necrotizing pancreatitis with sterile necrosis. Necrotizing pancre-
atitis with infected necrosis was induced by the injection of 2 ml/kg
4% sodium taurocholate solution followed by 2ml/kg 1.0 108 CFU/
ml Escherichia coli solution (XL blue, Stratagene, Santa Clara, CA,
USA). Sham operated animals were treated with 4 ml/kg 0.9% so-
dium chloride injection into the common bile duct which induced
mild edema to the pancreas. Animals were sacriﬁced by cardiac
puncture under general anesthesia between 6 and 120 h after
pancreatitis induction. After laparotomy, organs were harvested
and a broncho-alveolary lavage was performed. Histomorpho-
logical, microbiological and biochemical analysis of pancreatitis
severity was determined in these animals and described in detail in
previous publications [9,10]. Serum was immediately harvested
after centrifugation at 13,000  g for 10 min at 4 C and frozen in
liquid nitrogen. Samples were stored at 80 C until further
processing.
A Mouse Antibody Array 1 (Ray Biotech, Norcross, GA, USA)
protein array was performed with pooled samples from 5 animals
each with samples taken after 6, 12, 24, 48, and 120 h after treat-
ment with saline, taurocholate, or taurocholate and bacteria. Serum
pools were diluted 1:5 with phosphate buffered saline. The
following procedures were performed according to the manual
provided by the supplier. Shortly, after primary dialysis sample
proteins were biotinylated, the reaction was quenched and a sub-
sequent dialysis was performed. Biotinylated samples were mixed
1:40 with blocking buffer. After blocking the array with blocking
buffer for 30 min at room temperature, the array was hybridized
over night at 4 C. The array was then washed; ﬁrst with washing
buffer I followed bywashing buffer II. The array was then incubated
with ﬂuorescent dye conjugated streptavidin for 2 h at room
temperature. After washing, the array was dried and stored
at 20 C until readout. The readout was performed with an Axon
GenePix laser scanner using the Cy3 channel. Analysis was per-
formed using ScanAlyze Ver. 2.35 (http://www.eisenlab.org). The
threshold was set to two times the empty signal. An increase in
protein concentrationwas deemed in spots withmore than a 2-fold
increase in ﬂuorescence intensity. Decreased protein concentration
was presumed in spots with more than 50% decreased ﬂuorescenceintensity. Only proteins showing regulation at more than 2 time
points were considered for further analysis.
Sandwich ELISA
Mouse CCL17/TARC, mouse IL-13, mouse TRANCE/TNSF11/RANK
ligand, mouse Fc gamma RIIB/CD32b and mouse IFN-g R1 DuoSet
ELISA Development Systems (R&D Systems,Minneapolis, MN; USA)
were used for sandwich ELISA. Shortly, 384 well plates were coated
with capture antibody in concentrations depending on the ELISA
set ranging from 0.4 mg/ml to 4 mg/ml and blocked with blocking
buffer (1% BSA in PBS). 10 ml of serum, sample buffer or standards
with known concentrationwere added to thewells in duplicate and
incubated for 2 h at room temperature. After washing, 10 ml of the
detection antibody solution (50e200 hg/ml) were added in each
well and incubated for 2 h at room temperature. After washing,
10 ml of Streptavidin-horseradish peroxidase solution were added
and incubated for 20 min at room temperature. After washing
again, substrate solution was added and the reaction was stopped
after 20 min by adding 2 ml of 0.5 M EDTA. Absorbance was
monitored at 450 hm, and the absorption at 550 hm was
subtracted.
Human blood samples
Human samples were obtained from patients admitted to the
Helsinki Central Hospital from 1998 to 2010. The study protocol
was approved by the local ethics committee, and informed consent
was obtained in all cases. Samples were taken from patients with
severe acute pancreatitis andmild acute pancreatitis categorized by
the revised Atlanta classiﬁcation [1]. Patients with severe pancre-
atitis were further categorized in patients with conﬁrmed infection
of pancreatic necrosis by bacteriological analysis of tissue speci-
mens and patients without intraabdominal infection. Patients with
mild acute pancreatitis served as controls. Plasma samples in pa-
tients with severe pancreatitis were taken approximately two
weeks after onset of symptoms, while in patients with mild
pancreatitis samples were taken on average 3.6 days (±0.40 days)
after onset of disease due to the rapid resolution of disease. Patient
characteristics are shown in detail in Table 1. Serum concentrations
of CXCL16 and TRANCE were determined by sandwich ELISA pur-
chased from R&D using the ELISA conditions suggested by the
supplier and the method described for murine samples. CRP was
determined by routine laboratory procedures.
Fig. 1. Antibody protein array. Sera from ﬁve animals per treatment and time point
were pooled and hybridized to the protein array chip, and ﬂuorescence was measured.
The relative concentrations between sham treatment and sterile necrosis, sham
treatment and infected necrosis, as well as between sterile and infected necrosis are
shown. Red boxes represent a more than 2-fold increase in protein concentration,
while green boxes represent a decrease in serum concentration by more than 50%.
Special regard was paid to proteins showing regulation during the early course of acute
pancreatitis in animals with infected necrosis when compared to sham treatment and
animals with sterile necrosis (C e sham operated control, SNesterile necrosis, IN e
infected necrosis).
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The datawere analyzed using SPSS Software (SPSS, Version 21.0,
SPSS Inc. Chicago IL, USA) and are displayed as mean ± standard
error of the mean for murine samples. Human samples were dis-
played asmedian and upper and lower quartile. Equality of variance
was tested using the Levene-Test. Statistical signiﬁcance was
analyzed using univariate analysis of variance. When equality of
variance was not achieved, a Kruskal-Wallis-Test for independent
samples was performed. Receiver operated characteristics were
determined for clinical samples, and the area under the curve was
calculated. Statistical signiﬁcance is assumed for p < 0.05.
Results
Sera were obtained from sham treated animals suffering from
mild pancreatic edema, severe necrotizing pancreatitis with sterile
necrosis induced by taurocholate injection, and severe necrotizing
pancreatitis with infected pancreatic necrosis. Sampleswere pooled
before being hybridized to the antibody array chip. Each serum pool
consisted of sera obtained from ﬁve animals per treatment and time
point.We examined sera at 6,12, 24, 48, and 120 h after induction of
acute pancreatitis. 304 proteins were represented on the array chip,
199 could not be detected (65.5%). Of the 105 detected proteins, 28
were only detected in one spot and were not further evaluated. 34
(11.18%) of the remaining proteins did not show alterations or were
only altered at one time point of the experiment. Only for 43 tested
proteins (14.44%), different serumconcentrationswere found at 2 or
more time points. These results are shown in Fig. 1. Proteins of
distinct interestwere characterized by differences between infected
and sterile necrosis as well as between infected necrosis and sham
treated animals. Furthermore, proteins that were regulated early on
were favored. Finally, CD32b (Fc gamma RIIB), TNFSF11 (TRANCE,
RANK Ligand), CXCL16, TARC (CCL17), IFN-gR1 (CD119), and CD13
were selected and further examined by sandwich ELISA.
To examine if pancreatic necrosis, bacterial infection or even the
combination of both is required for the increase in the serum con-
centration of the proteins examined, animals were treated by sham
treatmentwith saline injection, pancreatic bacterial injectionwithout
inducing pancreatic necrosis, induction of sterile necrosis, and in-
duction of infected necrosis. Serum was obtained 24 h after the in-
duction of treatment. In these experiments, IFN-gR1 and IL13 did not
differ signiﬁcantly between the treatment groups (Fig. 2Dþ E). CCL17
concentration depended on the presence of bacterial infection and
was independent of pancreatic necrosis (Fig. 2A), while serum
TRANCE and CXCL16 were increased in animals with necrotizing
pancreatitis (Fig. 2C þ F). In most of the sham treated animals and
animals with bacteria injection only, TRANCE concentration was
below the detection limit (Fig. 2F). CXCL16 concentrations were the
highest in animals with infected pancreatic necrosis, while animals
with injection of bacteria alone and animals with sterile pancreatic
necrosis showed considerably lower CXCL16 concentrations (Fig. 2C).
To conﬁrm the results and validate these ﬁndings, we examined
these parameters in a group of patients with acute pancreatitis. This
group included patients with mild pancreatitis (Marshal score 0,
n ¼ 12), patients with severe pancreatitis without abdominal
infection (Marshal score 2, n ¼ 21) and patients with severe
pancreatitis and proven infection of pancreatic necrosis or open
abdomen (Marshal score 2, n ¼ 14. In 6 patients pneumonia was
documented as an extraabdominal infection. Patient characteristics
are summarized in Table 1. In all patients, C-reactive protein,
CXCL16 and TRANCE were determined. C-reactive protein did not
differ signiﬁcantly between the three groups and showed sub-
stantially elevated CRP values even in patients with mild pancrea-
titis, possibly due to early sample taking after onset of disease.Similar to C-reactive protein, serum TRANCE levels did not differ
signiﬁcantly between these groups. By contrast to TRANCE and C-
reactive protein, CXCL16 was increased in severe pancreatitis, but
was further increased in patients with severe pancreatitis and
abdominal infection. (See Fig. 3)
Examination of the receiver operating characteristic showed
that C-reactive protein concentration and TRANCE concentration
were bad predictors of bacterial infection in necrotizing pancrea-
titis (Fig. 4). CXCL16, on the other hand, was determined to be a
good predictor of infection during necrotizing pancreatitis with an
area under the curve of 0.844 (95% CI 0.730e0.957). This indicates
the usefulness of determining serum CXCL16 to identify patients
with abdominal infection in necrotizing pancreatitis.
Discussion
We demonstrate that CXCL16 is increased in mice with necro-
tizing pancreatitis and infected pancreatic necrosis. In humanswith
Fig. 2. Sandwich ELISAs of mouse serum samples. ELISAs were performed with sera obtained from mice with necrotizing pancreatitis, sterile pancreatic necrosis and infected
pancreatic necrosis. These animals were compared to animals with intra-pancreatic bacterial infusion and animals with sham treatment. A e Serum CCL17 concentration: CCL17
serum concentrations were increased in animals with bacterial infection. Animals with pancreatic necrosis did not show increased CCL17 serum concentrations (p < 0.05). B e
Serum CD32B concentration: CD32B concentrations were determined in sera from animals treated with taurocholate, bacteria, or a combination thereof. CD32B concentrations did
not differ signiﬁcantly between these treatment groups. C e Serum CXCL16 concentration: Serum CXCL16 concentrations were increased in animals with infected pancreatic
necrosis (p < 0.05). D e Serum IFNgR1 concentration: Serum IFNgR1 concentration was not signiﬁcantly altered between the treatment groups 24 h after induction of necrotizing
pancreatitis with and without infection of pancreatic necrosis. E  Serum IL-13 concentration: Results from the protein array were not conﬁrmed by serum sandwich ELISA of IL-13.
In fact, IL13 was reduced in animals with sterile necrotizing pancreatitis, and in animals with infected necrosis, concentrations were similar to sham treated animals. F e TRANCE
ELISA: In contrast to sham treated animals and animals with bacterial infection TRANCE was detected in serum in animals with sterile necrosis. Infection of pancreatic necrosis
signiﬁcantly increased the serum concentrations of TRANCE in mice (p < 0.005).
U.A. Wittel et al. / Pancreatology 15 (2015) 124e130 127severe necrotizing pancreatitis, CXCL16 was able to discriminate
between patients with or without infection of pancreatic necrosis.
Other markers that were identiﬁed initially in animal experiments
did not fulﬁll their expectations and could not distinguish betweeninfected and sterile pancreatic necrosis in humans. These markers
were elevated in patients with pancreatic necrosis independent of
infection as well as in animals with abdominal infection indepen-
dent of the presence of pancreatitis. The ﬁrst observationwas made
Fig. 3. Serum concentrations in patients with necrotizing pancreatitis. Serum from
patients with mild pancreatitis, severe pancreatitis without infected pancreatic ne-
crosis and severe pancreatitis with infected necrosis was used to determine the con-
centration of C-reactive protein, TRANCE, and CXCL16. A e C-reactive protein did not
show signiﬁcant alterations between the groups tested. B e TRANCE did not show
distinct alterations of serum concentrations in patients with infection compared to
patients without infection of pancreatic necrosis. Additionally, even patients with mild
pancreatitis showed substantially increased TRANCE concentrations. C e CXCL16
concentrations were only slightly increased in patients with severe pancreatitis
compared to patients with mild pancreatitis. However, when infection of pancreatic
necrosis was present, CXCL16 concentrations were signiﬁcantly increased (p < 0.001),
indicating a correlation with the infection of pancreatic necrosis.
Fig. 4. ROC-curves of patient samples. Rreceiver operated characteristics cuves were
plotted to examine the prediction of infection of pancreatic necrosis by an increase of
serum C-reactive protein, TRANCE, and CXCL16. CXCL16 showed the largest area under
the curve of 0.844, indicating that CXCL16 is a good predictor of infected pancreatic
necrosis.
U.A. Wittel et al. / Pancreatology 15 (2015) 124e130128for serum TRANCE, which was increased in patients with sterile as
well as in patients with infected necrosis. The role of TRANCE in
acute pancreatitis as well as in acute inﬂammation is not clear to
date, but TRANCE appears to counteract a CD40L initiated immune
response and seems to be involved in themediation of Treg induced
suppression of Th1 autoimmunity [11,12]. Despite promising ani-
mal data, TRACE did not serve as a marker of infected pancreatic
necrosis in patients with necrotizing pancreatitis and multiple-
organ failure. By contrast, in the case of CXCL16 the area under
the receiver operated characteristics curve was estimated to be
0.844 in the same collective of patients with infected pancreatic
necrosis in necrotizing pancreatitis. This indicates a positive pre-
dictive value for CXCL16 in identifying patients with infected
pancreatic necrosis in severe necrotizing pancreatitis. Furthermore,
CXCL16 elevations appeared to be speciﬁc for abdominal infections
since patients with pneumonia and severe pancreatitis without
infection of necrosis did not show induce a raise in CXCL16
concentration.
Biomarkers to detect ormonitor infection are a topic of intensive
research. They can be classiﬁed by their origin or by their function.
While pro-inﬂammatory cytokines such as tumor necrosis factor,
IL-1b, IL-6, or chemokines as IL-8 mediate the ﬁrst response to
injury or infection they subsequently trigger the inﬂammatory
cascade [13e16]. They also trigger the synthesis of the routinely
used acute phase proteins such as C-reactive protein and pro-
calcitonin [17,18]. In addition to these biomarkers, biomarkers
released by activated immune cells can be monitored. These are
CD64, CD11b, triggering receptor expressed on myeloid cells-1
(TREM-1), or neutrophil gelatinase-associated lipocalin (NGAL)
[19e21]. Due to their biological function, this family of biomarkers
which also includes CXCL16 promises to effectively diagnose and
monitor systemic inﬂammatory events.
CXCL16 is expressed on antigen presenting cells, mostly den-
dritic cells and macrophages where it has several functions
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brane bound molecule, CXCL16 is involved in phagocytosis of bac-
teria and acts as a scavenger receptor for oxidized LDL [24,25].
Additionally, it interacts with CXCR6 expressing cells [26]. Finally,
the extracellular domain of CXCL16 can be shed in an MMP10
dependent manner whereas CXCL16 displays chemotactic proper-
ties on leukocytes as well as on mesenchymal cells [27e32]. Acti-
vated lymphocytes almost abundantly express the CXCL16 receptor
CXCR6, indicating that the action of CXCL16 is not restricted to
phagocytes [33]. Interestingly, CXCL16 is expressed in chronic
pancreatitis and pancreatic cancer by ductal cells and is increas-
ingly shed since soluble CXCL16 levels are increased in pancreatic
disorders when compared to healthy controls [34,35]. While in
necrotizing pancreatitis with infected necrosis the probable action
of CXCL16 appears to be leukocyte recruitment, CXCL16 is also
involved in other immunological pathways. CXCL16 is part of the
adaptive immune response since CXCL16 knockout mice show a
reduced T-helper 1 mediated immune response [36].
In arteriosclerosis, CXCL16 mediates the uptake of atherogenic
lipoproteins by macrophages and smooth muscle cells and there-
fore mediates the formation of arteriosclerotic plaques [37]. In the
pancreas and maybe even in pancreatic cancer, the chemotactic
properties of CXCL16 on mesenchymal cells may contribute to the
movement of these cells into the pancreas and may therefore
contribute to ﬁbrosis and healing after acute pancreatitis or during
the development of chronic pancreatitis or pancreatic cancer [29].
In summary, we identiﬁed CXCL16 as a serum marker that is
elevated in infected pancreatic necrosis experimentally and in the
clinical setting. CXCL16 may hereby be part of the immunological
transition that aggravates the severity of the systemic inﬂamma-
tory response upon infection of pancreatic necrosis. To conﬁrm the
usefulness CXCL16 in identifying patients with necrotizing
pancreatitis that require surgical intervention, studies investigating
the time course of CXCL16 concentrations during the development
of infection of pancreatic necrosis in necrotizing pancreatitis have
to be performed.Acknowledgment
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